Loading…
Beta Drugs (BETA)₹1,882+3.44%Pharmaceuticals
In the Sep 2026 quarter (consolidated), Beta Drugs reported sales of ₹137 Cr, up 33.0% from Sep 2025, and net profit of ₹19.07 Cr, up 58.3% year on year. For the year to Mar 2026, sales were ₹384 Cr and net profit ₹41.18 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 88.03 | 94.01 | 100 | 103 | 87.08 | 94.10 | 126 | 137 |
| Expenses | 69.89 | 75.86 | 80.86 | 81.93 | 69.91 | 75.91 | 97.82 | 107 |
| Operating Profit | 17.92 | 16.93 | 19.93 | 20.91 | 16.94 | 17.93 | 26.88 | 29.86 |
| OPM % | 21.0% | 18.0% | 20.0% | 21.0% | 19.0% | 19.0% | 22.0% | 22.0% |
| Other Income | −1.01 | 2.01 | 3.01 | 3.01 | 2.01 | 3.01 | 2.01 | 2.01 |
| Interest | 1.99 | 2.99 | 2.99 | 3.99 | 3.99 | 3.99 | 2.99 | 1.99 |
| Depreciation | 2.99 | 3.99 | 3.99 | 3.99 | 3.99 | 4.98 | 3.99 | 4.98 |
| Profit before tax | 11.97 | 11.97 | 15.97 | 15.96 | 9.98 | 11.96 | 21.96 | 25.95 |
| Tax % | 25.0% | 26.0% | 25.0% | 26.0% | 19.0% | 24.0% | 25.0% | 25.0% |
| Exceptional items | −2.01 | −2.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 9.04 | 9.03 | 12.04 | 12.05 | 9.04 | 9.04 | 16.06 | 19.07 |
| EPS (Rs) | 8.85 | 8.94 | 11.57 | 12.10 | 8.39 | 8.91 | 14.24 | 16.66 |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 51.06 | 66.03 | 91.04 | 116 | 184 | 227 | 296 | 362 | 384 | 444 |
| Expenses | 40.93 | 53.88 | 72.87 | 90.91 | 141 | 174 | 236 | 286 | 309 | 350 |
| Operating Profit | 8.97 | 11.95 | 17.92 | 24.91 | 42.86 | 52.82 | 59.80 | 74.69 | 75.72 | 91.61 |
| OPM % | 19.0% | 18.0% | 20.0% | 21.0% | 23.0% | 23.0% | 20.0% | 21.0% | 20.0% | 20.6% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 1.01 | 1.01 | 2.01 | 11.05 | 9.04 |
| Interest | 0.99 | 0.99 | 2.99 | 1.99 | 1.99 | 1.99 | 2.99 | 6.99 | 14.99 | 12.96 |
| Depreciation | 1.99 | 2.99 | 3.99 | 6.97 | 6.98 | 9.96 | 9.96 | 12.96 | 16.93 | 17.94 |
| Profit before tax | 6.99 | 7.98 | 11.98 | 15.98 | 33.92 | 40.89 | 48.87 | 56.85 | 53.84 | 69.85 |
| Tax % | 1.0% | −2.0% | 21.0% | 27.0% | 28.0% | 25.0% | 25.0% | 26.0% | 24.0% | — |
| Exceptional items | 0.00 | 0.00 | −0.03 | 0.00 | 0.00 | 0.00 | 0.00 | −3.38 | 0.00 | 0.00 |
| Net Profit | 7.02 | 8.03 | 9.04 | 12.05 | 25.10 | 31.12 | 36.15 | 42.16 | 41.18 | 53.21 |
| EPS (Rs) | 7.42 | 8.83 | 9.32 | 11.59 | 24.56 | 30.37 | 36.06 | 41.95 | 40.84 | 48.20 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9.02 | 9.02 | 10.02 | 10.02 | 10.02 | 10.02 | 10.01 | 10.02 | 10.02 |
| Reserves | 24.01 | 32.05 | 48.03 | 59.05 | 83.06 | 113 | 148 | 187 | 235 |
| Borrowings | 7.99 | 19.98 | 22.99 | 16.99 | 21.01 | 19.99 | 14.97 | 138 | 148 |
| Other Liabilities | 9.04 | 22.10 | 28.13 | 31.15 | 45.22 | 55.26 | 82.34 | 101 | 103 |
| Total Liabilities | 50.06 | 83.15 | 107 | 118 | 158 | 198 | 254 | 437 | 497 |
| Fixed Assets | 12.99 | 17.99 | 44.01 | 39.95 | 54.99 | 62.97 | 64.92 | 88.89 | 125 |
| CWIP | 1.01 | 15.05 | 0.00 | 3.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 1.01 | 1.01 | 1.01 | 0.00 | 0.00 | 0.00 |
| Other Assets | 35.06 | 50.11 | 63.16 | 74.24 | 102 | 135 | 190 | 348 | 372 |
| Inventories | 3.01 | 10.03 | 12.03 | 16.04 | 22.05 | 31.09 | 50.17 | 60.14 | 74.26 |
| Trade receivables | 13.97 | 24.94 | 31.93 | 33.94 | 44.90 | 62.86 | 78.81 | 103 | 119 |
| Cash & equivalents | 12.01 | 2.99 | 4.99 | 9.99 | 17.01 | 18.99 | 28.98 | 147 | 125 |
| Total Assets | 50.06 | 83.15 | 107 | 118 | 158 | 198 | 254 | 437 | 497 |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 17.06 | 0.00 | 8.02 | 19.08 | 30.08 | 23.07 | 31.10 | 36.11 | 37.15 |
| Cash from investing activity | −11.04 | −21.10 | −15.06 | −6.03 | −22.09 | −19.09 | −14.05 | −36.13 | −51.23 |
| Cash from financing activity | 5.01 | 12.03 | 9.03 | −8.03 | −1.01 | −2.01 | −7.02 | 118 | −8.02 |
| Net cash flow | 11.99 | −8.99 | 1.99 | 4.99 | 6.99 | 1.99 | 8.99 | 118 | −21.97 |
| Capex | 8.02 | 21.02 | 15.02 | 6.01 | 19.04 | 18.03 | 12.02 | 37.09 | 53.05 |
| Free cash flow | 9.02 | −21.03 | −7.01 | 13.03 | 10.02 | 5.01 | 19.04 | −1.01 | −16.04 |
| CFO / OP % | 181.0% | 1.0% | 47.1% | 75.1% | 69.1% | 44.0% | 52.0% | 48.0% | 49.1% |
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 103 | 138 | 127 | 105 | 89 | 100 | 97 | 102 | 112 |
| Inventory days | 37 | 104 | 102 | 100 | 87 | 106 | 122 | 127 | 159 |
| Days payable | 81 | 143 | 119 | 127 | 123 | 139 | 145 | 152 | 172 |
| Cash conversion cycle | 60 | 100 | 111 | 79 | 53 | 68 | 75 | 79 | 100 |
| Working capital days | 49 | 39 | 55 | 75 | 60 | 72 | 79 | 70 | 96 |
| ROCE % | — | 18.0% | 21.1% | 22.0% | 36.0% | 34.1% | 33.0% | 27.0% | 19.0% |
For the Sep 2026 quarter, Beta Drugs reported sales of ₹137 Cr, up 33.0% year on year and net profit of ₹19.07 Cr, up 58.3% year on year. The operating margin was 22.0%.
Beta Drugs' sales for the year to Mar 2026 were ₹384 Cr; over the last twelve months they were ₹444 Cr.
Net profit for the year to Mar 2026 was ₹41.18 Cr, and ₹53.21 Cr over the last twelve months. Earnings per share over the same trailing period were ₹48.20.
Beta Drugs reported borrowings of ₹148 Cr at Mar 2026, against cash and equivalents of ₹125 Cr.
Cash from operations was ₹37.15 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹16.04 Cr.